Sonata Therapeutics
Sabin Dhakal, PhD, currently serves as a Principal Scientist in Cancer Biology at Sonata Therapeutics, specializing in developing innovative anti-cancer therapies that leverage immune system synergy. Previous roles include Entrepreneurial Fellow at Celdara Medical, conducting due diligence on biological and pharmaceutical assets, and a Postdoctoral Fellow at Harvard Medical School, where research focused on intratumoral heterogeneity and its effects on tumor progression. Sabin's background includes a comprehensive education in biological sciences, with a PhD from Harvard University in Cancer Biology, and experience in leadership and mentorship through various programs at prestigious institutions, such as the Harvard Graduate Business Club and the Science Diplomacy Center at Tufts University.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.